(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 November 2019 (28.11.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/227029 A1

(51) International Patent Classification:
C12N 9/16 (2006.01)

(21) International Application Number:
PCT/US2019/033983

(22) International Filing Date:
24 May 2019 (24.05.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/676,525 25 May 2018 (25.05.2018) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 50 Binney Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **YANG, Mark**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **BUSER, Claudia**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **PEREZ-RAMIREZ, Bernardo**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **TRIERWEILER, Grant**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **BENJWAL, Sangeeta**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US).

(74) Agent: **LI, Z. Ying** et al.; Steptoe & Johnson LLP, 1330 Connecticut Avenue, N.W., Washington, District of Columbia 20036 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: PHARMACEUTICAL COMPOSITIONS FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY

(57) Abstract: The present invention provides compositions such as aqueous liquid compositions and lyophilized compositions comprising a recombinant human acid sphingomyelinase. Provided also are methods for using the compositions to treat patients who are deficient in acid sphingomyelinase.

WO 2019/227029 A1